Status:
COMPLETED
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive p...
Eligibility Criteria
Inclusion
- A clinical diagnosis of COPD with symptoms for more than 2 years.
- Smoking history of 10 or more pack years
- A history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before first visit.
Exclusion
- A history of asthma
- Patients taking oral steroids
- Any significant disease or disorder that may jeopardize the safety of the patient
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2007
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT00206167
Start Date
April 1 2005
End Date
September 1 2007
Last Update
March 27 2009
Active Locations (216)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Huntsville, Alabama, United States
3
Research Site
Jasper, Alabama, United States
4
Research Site
Muscle Shoals, Alabama, United States